Published in J Clin Pathol on January 01, 1999
Improving the care of patients with genital herpes. BMJ (2000) 1.11
Genital herpes in Canada: Deciphering the hidden epidemic. Can J Infect Dis Med Microbiol (2012) 0.75
Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol (1988) 8.09
Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med (1997) 7.59
Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med (1995) 4.03
Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl (1990) 4.02
Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med (1994) 3.83
The acquisition of herpes simplex virus during pregnancy. N Engl J Med (1997) 3.73
Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ (1994) 3.71
A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med (1989) 2.94
Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis (1985) 2.64
Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J Clin Microbiol (1985) 2.54
Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med (1992) 2.25
Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies. J Clin Microbiol (1998) 2.10
A novel glycoprotein for detection of herpes simplex virus type 1-specific antibodies. J Virol Methods (1986) 1.98
Detection of immunoglobulin M antibodies to glycoprotein G-2 by western blot (immunoblot) for diagnosis of initial herpes simplex virus type 2 genital infections. J Clin Microbiol (1993) 1.83
Changing presentation of herpes simplex virus infection in neonates. J Infect Dis (1988) 1.76
Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis (1997) 1.60
Monoclonal antibody blocking tests for the detection of HSV-1- and HSV-2-specific humoral responses: comparison with western blot assay. J Virol Methods (1995) 1.49
Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis (1994) 1.31
Asymptomatic shedding and subsequent transmission of genital herpes simplex virus. Genitourin Med (1987) 1.23
Frequency of asymptomatic shedding of herpes simplex virus in women with genital herpes. JAMA (1990) 1.18
Screening to detect asymptomatic shedding of herpes simplex virus (HSV) in women with recurrent genital HSV infection. Genitourin Med (1986) 1.11
Expression of HSV-1 and HSV-2 glycoprotein G in insect cells by using a novel baculovirus expression vector. Virology (1991) 1.07
Comparison of cell culture with an amplified enzyme immunoassay for diagnosing genital herpes simplex infection. J Clin Pathol (1991) 0.99
Epidemiology of genital herpes infections. Infect Dis Clin North Am (1993) 0.89
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut (2000) 2.16
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med (2003) 1.94
Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom. J Clin Microbiol (2001) 1.75
Implications for HIV testing policy derived from combining data on voluntary confidential testing with viral sequences and serological analyses. Sex Transm Infect (2008) 1.66
The Bacillus subtilis spoVD gene encodes a mother-cell-specific penicillin-binding protein required for spore morphogenesis. J Mol Biol (1994) 1.64
Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother (2005) 1.63
Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother (1980) 1.61
Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS (1992) 1.56
Direct visualization and quantitation of cytomegalovirus-specific CD8+ cytotoxic T-lymphocytes in liver transplant patients. Transplantation (2000) 1.48
Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus. Antimicrob Agents Chemother (1999) 1.41
Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS (2007) 1.40
HIV and hepatitis C coinfection within the CAESAR study. HIV Med (2004) 1.39
Antimicrobial agents from higher plants. Antimicrobial agents from Peganum harmala seeds. J Nat Prod (1982) 1.38
Antibodies to adeno-associated satellite virus and herpes simplex in sera from cancer patients and normal adults. Am J Obstet Gynecol (1976) 1.32
Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther (2004) 1.28
Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). HIV Med (2010) 1.24
Detection of drug resistance associated mutations in HIV primary infection within the UK. AIDS (2000) 1.24
B94, a primary response gene inducible by tumor necrosis factor-alpha, is expressed in developing hematopoietic tissues and the sperm acrosome. J Biol Chem (1994) 1.22
Investigation of vesicular rashes for HSV and VZV by PCR. J Med Virol (1998) 1.20
High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol (1999) 1.17
A modern look at folkloric use of anti-infective agents. J Nat Prod (1988) 1.15
Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. J Antimicrob Chemother (2001) 1.14
Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS (2000) 1.14
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med (2009) 1.14
Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir Ther (2001) 1.14
HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Med (2007) 1.11
Improving the care of patients with genital herpes. BMJ (2000) 1.11
Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation (1993) 1.09
Recombinant strains of HIV type 1 in the United Kingdom. AIDS Res Hum Retroviruses (2001) 1.08
Characterization of a nested polymerase chain reaction assay for detection of parvovirus B19. J Clin Microbiol (1993) 1.07
The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. J Viral Hepat (2009) 1.07
Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasma. Sex Transm Infect (1999) 1.06
An open, comparative, study of the efficacy of 0.5% podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminata in males and females. Int J STD AIDS (1993) 1.05
Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology (2011) 1.05
Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS (1999) 1.05
Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antivir Ther (1999) 1.04
Detection of adenovirus by enzyme-linked immunosorbent assay. J Clin Microbiol (1979) 1.03
The effects of urethritis on seminal plasma HIV-1 RNA loads in homosexual men not receiving antiretroviral therapy. Sex Transm Infect (2005) 1.03
Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease. HIV Med (1999) 1.03
Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. HIV Med (2011) 1.03
A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. Antimicrob Agents Chemother (1997) 1.01
6-Thioguanine-induced DNA damage as a determinant of cytotoxicity in cultured Chinese hamster ovary cells. Cancer Res (1984) 1.00
British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Med (2010) 1.00
Use of next-generation sequencing and candidate gene analysis to identify underlying defects in patients with inherited platelet function disorders. J Thromb Haemost (2015) 0.99
Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. AIDS (2001) 0.96
Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis (2000) 0.96
Diagnosis of primary human herpesvirus 6 and 7 infections in febrile infants by polymerase chain reaction. Arch Dis Child (1997) 0.96
An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS (2003) 0.95
Perinatal lipogenesis in the liver and brown adipose tissue of the rat. Int J Biochem (1982) 0.94
Characterization of HIV type 1 clades in the Caribbean using pol gene sequences. AIDS Res Hum Retroviruses (2003) 0.94
Towards error-free HIV diagnosis: guidelines on laboratory practice. Commun Dis Public Health (2003) 0.93
Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India. Indian J Med Microbiol (2009) 0.93
Risk factors, clinical features and genotype distribution of diagnosed hepatitis C virus infections: a pilot for a sentinel laboratory-based surveillance. Commun Dis Public Health (2003) 0.93
JC virus associated meningoencephalitis in an immunocompetent girl. Arch Dis Child (1992) 0.92
Adenovirus infections following haematopoietic cell transplantation: is there a role for adoptive immunotherapy? Bone Marrow Transplant (2000) 0.92
What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother (2008) 0.91
Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis (2000) 0.91
Audit of endoscopic surveillance biopsy specimens in HIV positive patients with gastrointestinal symptoms. Gut (1993) 0.91
Liposomal enhancement of the immunogenicity of adenovirus type 5 hexon and fiber vaccines. Infect Immun (1979) 0.91
A multiplex PCR assay for the simultaneous detection of human herpesvirus 6 and human herpesvirus 7, with typing of HHV-6 by enzyme cleavage of PCR products. J Virol Methods (1998) 0.91
New clinics for HIV testing. Upgrade existing services. BMJ (1993) 0.90
Relatedness of Thermomyces lanuginosus strains producing a thermostable xylanase. J Biotechnol (2000) 0.89
Random-amplified polymorphic DNA (RAPD) analysis shows intraspecies differences among Xanthomonas albilineans strains. Lett Appl Microbiol (1996) 0.88
Parainfluenza virus type 3 infections in hematopoetic stem cell transplant recipients: response to ribavirin therapy. Clin Infect Dis (2000) 0.88
Haloalkane and haloacid dehalogenases from aerobic bacterial isolates indigenous to contaminated sites in Africa demonstrate diverse substrate specificities. Chemosphere (2004) 0.87
Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia. Clin Pharm (1985) 0.87
Cytomegalovirus infection and risk of AIDS in human immunodeficiency virus-infected hemophilia patients. National Cancer Institute Multicenter Hemophilia Cohort Study Group. J Infect Dis (1993) 0.87
Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection. Antivir Ther (2000) 0.87
A disability perspective from the United States on the case of Ms B. J Med Ethics (2002) 0.86
Isolation of viruses from stools in stem cell transplant recipients: a prospective surveillance study. Bone Marrow Transplant (2000) 0.86
Potentiation of methotrexate toxicity by dipyridamole. Cancer Res (1984) 0.86
The frequency of HIV-I drug resistance mutations among treatment-naive individuals at a tertiary care centre in south India. Int J STD AIDS (2009) 0.86
Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. Infect Genet Evol (2006) 0.86
Laparoscopic anterior esophageal myotomy and toupet fundoplication for achalasia. Am Surg (2001) 0.86
Predictive value of the ultrasensitive HIV viral load assay in clinical practice. J Med Virol (2000) 0.85
Prevalence of long-term BK and JC excretion in HIV-infected adults and lack of correlation with serological markers. J Med Virol (1999) 0.84
Dynamics of seminal plasma HIV-1 decline after antiretroviral treatment. AIDS (2001) 0.84
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring. Antimicrob Agents Chemother (2011) 0.84
Cell cytotoxicity due to specific influenza antibody production in vitro after recent influenza antigen stimulation. Proc Natl Acad Sci U S A (1979) 0.83
Lipogenesis at the suckling-weaning transition in liver and brown adipose tissue of the rat. Biochim Biophys Acta (1982) 0.83
Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut (2001) 0.82
Antiviral drug resistance: from the laboratory to the patient. Antivir Ther (1998) 0.82
Isolation and identification of trachyloban-19-oic and (-)-kaur-16-en-19-oic acids as antimicrobial agents from the prairie sunflower, Helianthus annuus. J Nat Prod (1984) 0.81
Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med (2011) 0.81
Effects of insulin and maternal diabetes on fetal lipogenesis in the rat. Enzyme (1983) 0.81
Semen characteristics in HIV-1 positive men and the effect of semen washing. Genitourin Med (1997) 0.80
Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies. Int J Clin Pract (2006) 0.80
Antimicrobial agents from higher plants. Dragon's blood resin. J Nat Prod (1983) 0.80
A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators. J Acquir Immune Defic Syndr (2005) 0.80
Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study. Genitourin Med (1997) 0.80
Solid organ transplantation in patients with HIV infection. Transplantation (2001) 0.79
The impact of HIV-1 subtype on drug resistance. J HIV Ther (2001) 0.79
Audit of HIV RNA quantitation measurements in the West Midlands: a preliminary report. Collaborating HIV Physicians. Int J STD AIDS (1998) 0.79
The prevalence of reduced zidovudine susceptibility in zidovudine-naive, antiretroviral-experienced HIV-1-infected patients. HIV Med (2003) 0.79
BK virus-associated haemorrhagic cystitis in an HIV-infected man. AIDS (1994) 0.79
Antibiotic susceptibility patterns and plasmid profiles of penicillinase-producing Neisseria gonorrhoeae strains in Durban, South Africa, 1990-1993. Sex Transm Dis (1997) 0.78
Significance testing of clinical data using virus dynamics models with a Markov chain Monte Carlo method: application to emergence of lamivudine-resistant hepatitis B virus. Proc Biol Sci (1999) 0.78